Pharmaceutical Sales Company Deploys Work in 2017
Release time:
2020-08-14
Pharmaceutical Sales Company Deploys 2017 Work
News 1# September 15 , 24 , Peak Pharmaceutical Sales Company successively held terminal and agent annual summary meetings to review 2016 and deploy 2017 Work. At the terminal sales summary meeting held on January 15
2016 , summarizing the gains and losses of the work, analyzing the existing problems and exchanging the work plan for the new year. Xu Junxiong, executive deputy general manager of Pharmaceutical Sales Company, summarized the overall situation of terminal sales from the aspects of sales performance, specific work and existing problems. Focusing on the work focus of "increasing incentives, emphasizing academics and strengthening promotion", he made arrangements for the work of 2017 in terms of incentive mechanism, team building, bidding and bargaining, marketing innovation and academic promotion, and read out the 2017 terminal sales target decomposition plan and assessment criteria. Jin Xuecai, deputy general manager of Pharmaceutical Company and general manager of Pharmaceutical Sales Company, commented on the advantages and disadvantages of terminal sales 2016 at the meeting. According to the current development trend of the pharmaceutical industry, he asked all offices to seize the opportunity of medical insurance adjustment and strengthen hospital development. Strengthen communication and visit to achieve sales volume; Increase academic promotion and actively respond to trend changes; salesmen should strengthen their own training and learning, strengthen the internal management of the office; innovate the sales model and do a good job in terminal sales. At the
meeting, the level of salesmen was also evaluated according to their work performance, the collectives and individuals who won the annual sales competition award were commended, and the annual sales responsibility system was signed with each office. At the agency sales meeting held on January 24 , each regional manager summarized and reported the work in the first half of the year from the aspects of product sales, new customer development, existing problems, new year's work and goal realization. Regional managers and managers evaluate the reporter from five aspects, such as enterprise loyalty, sales performance over the years, annual sales performance, and market development ability, and ask questions about the main points of the report.
The meeting discussed and approved a new regional manager incentive and appraisal plan, announced the decision to merge several regions with smaller sales, and conducted a regional manager competition. Participants are ranked by the evaluation scores obtained in the previous report. The top ten regional managers give priority to regional bargaining. After three rounds of bidding, the competition results are finally determined. At the agent sales meeting, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, analyzed the current situation of the pharmaceutical industry from many aspects and pointed out the challenges and opportunities. He said that the incentive policy for regional managers will be adjusted, and he hopes that all regions will have a deep understanding of the new policy and resolutely implement it. Jiang Xiaomeng, chairman of
group company and chairman of pharmaceutical company, attended the agency sales meeting and delivered a speech. He commented on the agency sales work, pointed out that some personnel have problems such as lack of self-confidence, low morale, few methods, and serious inert thinking. Pharmaceutical sales companies are required to organize various trainings in a targeted manner, and sales personnel should also strengthen learning., Improve their own sales skills, think carefully according to the life cycle and sales strategy of the company's key products, and solve the problems in sales. (Ni Yingzhen Xu Xianzhong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page